Manufacturing

Articles

The companies have entered into an agreement for the technology transfer and clinical manufacturing of Mustang’s MB-107 lentiviral gene therapy program for the treatment of X-linked severe combined immunodeficiency, also known as bubble boy disease, in Europe.

Mustang Bio to Enter into Agreement with Minaris Regenerative Medicine for Gene Therapy Manufacturing in Europe

The agreement will allow Roche to use CEVEC’s proprietary ELEVECTA technology, which is designed to enable fully scalable, high-performance AAV vector production in suspension bioprocesses.

Roche in Agreement to Use CEVEC’s ELEVECTA Technology for AAV Manufacture

The HFC Disconnect Series from CPC (Colder Products Company) provides sterile disconnection of tubing used for single-use biopharma and cell and gene therapy manufacturing systems.

The HFC Disconnect Series for Cell and Gene Therapy Manufacturing

A virtual ribbon cutting, tour, and panel discussions were hosted on Oct. 29, 2020 to announce the opening of BioCentriq on the campus of the New Jersey Institute of Technology in Newark, NJ.

NJII Launches New Cell and Gene Therapy Development and Clinical Manufacturing Center

Bayer will own the rights to AskBio’s AAV-based gene therapy platform, its intellectual property portfolio, and an established CDMO.

Bayer to Acquire AskBio for up to $4 Billion

Orgenesis has completed its previously announced acquisition of Koligo Therapeutics with the additional acquisition of Tissue Genesis’ cell isolation technology, Icellator.  

Orgenesis Completes Koligo Acquisition and Gains Icellator Technology in Related Transaction

The new VirusExpress lentiviral production platform increases dose yields and reduces process development time for cell and gene therapies.

MilliporeSigma Launches Lentiviral Production Platform for Cell and Gene Therapies

Cytiva will provide the first FlexFactory to be used in the manufacture of pDNA to Akron Bio.

Akron Bio Will Install a Cytiva FlexFactory to Manufacture Plasmid DNA

Roche will use Dyno’s CapsidMap platform to develop next-generation adeno-associated virus vectors for gene therapies for central nervous system diseases and liver-directed therapies. 

Roche and Dyno Therapeutics to Enter into $1.8 Billion Collaboration 

Feliza Mirasol is the science editor for 

The manufacture of gene therapy vectors is shifting to more modern technologies.

Manufacturing, Gene Therapies